CUE News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

CU

Mkt Cap

$122.6M

Volume

99.87K

Next Earnings

November 11th

Loading chart

CU

CUECue Biopharma, Inc.

CUE

Pay with—

Available Balance0.00

CU

Mkt Cap

$135.6M

Volume

99.87K

Next Earnings

November 11th

Chart Financials Earnings News About Insider Filings

Head and Neck Squamous Cell Carcinoma (HNSCC) - Market Insights, Epidemiology, and Market Forecast - 2036 | Set to Reach $2.56 Billion as HPV-Targeted Vaccines Reshape CareThe HNSCC market is projected to grow from $850 million in 2025 to $2.56 billion by 2036 (10.5% CAGR), driven by HPV-targeted vaccines, checkpoint inhibitors, and biomarker-led patient selection. The US will remain the largest market at $2.082 billion. Key therapies include KEYTRUDA and OPDIVO, with emerging candidates like petosemtamab and amivantamab showing promise in clinical development.GlobeNewswire Inc. · Sep 30, 2026

Lift Therapeutics Appoints Daniel Passeri as Chief Executive OfficerLift Therapeutics announced the appointment of Daniel Passeri as CEO, bringing over 30 years of oncology drug development experience. Bo Rode Hansen transitions from Interim CEO to President and Board member. The company is preparing to advance its lead immuno-Modulatory Alpha Neutrophil (iMAN) program into first-in-human clinical studies in early 2027.GlobeNewswire Inc. · Sep 23, 2026

Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsightThe head and neck squamous cell carcinoma (HNSCC) market is expected to grow at a CAGR of 10.5% from 2026-2036, driven by rising cancer incidence, increased adoption of immunotherapies, and the launch of emerging novel treatments. The market was valued at USD 850 million in 2025 across seven major markets, with KEYTRUDA currently generating the highest revenue. Multiple companies are advancing innovative therapies targeting HPV16-positive HNSCC and other molecular pathways.GlobeNewswire Inc. · Jul 13, 2026

Cue Biopharma Announces $50.0 Million Private PlacementCue Biopharma secured $50 million in funding through a private placement led by Cormorant Asset Management and Columbia Threadneedle Investments. The company will use proceeds to advance clinical development of its immunological disorder therapies, including Phase 2 data expected from a CSU study in China by Q3 2026.GlobeNewswire Inc. · Jul 10, 2026

Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Cue Biopharma granted inducement equity awards to seven new employees on May 3, 2026, including newly appointed President and CEO Shao-Lee Lin, M.D., Ph.D. Dr. Lin received stock options for 655,074 shares and 327,537 restricted stock units, while six other new employees received aggregate options for 518,599 shares and 327,534 RSUs, all at an exercise price of $30.42 per share.GlobeNewswire Inc. · May 7, 2026

Cue Biopharma to Receive $7.5 Million Preclinical Milestone Payment from Boehringer Ingelheim Collaboration and License AgreementCue Biopharma announced it will receive a $7.5 million preclinical milestone payment from Boehringer Ingelheim following the selection and approval of the first compound for lead optimization under their collaboration agreement. The company is eligible for up to $337.5 million in additional milestone and royalty payments. Cue Biopharma continues advancing its lead autoimmune asset CUE-401 toward clinical development.GlobeNewswire Inc. · Apr 8, 2026

High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy HeadwindsDespite regulatory challenges and budget cuts, the oncology market is projected to reach US$900 billion by 2034, with several biotech companies advancing innovative cancer therapies and demonstrating promising clinical trial results.Benzinga · Jul 23, 2025

Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company’s Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune DiseaseCue Biopharma received positive feedback from the FDA on its pre-IND briefing document for CUE-401, a first-in-class bispecific molecule designed to induce and expand regulatory T cells for the treatment of autoimmune diseases. The company plans to file an IND for CUE-401 after completing final enabling studies.GlobeNewswire Inc. · Jun 24, 2025

Cue Biopharma Announces Pricing of Approximately $20 Million Public OfferingCue Biopharma, a clinical-stage biopharmaceutical company, announced the pricing of a public offering of its common stock and warrants, expected to raise approximately $20 million.Benzinga · Apr 15, 2025

Cue Biopharma Announces Pricing of Approximately $20 Million Public OfferingCue Biopharma, a clinical-stage biopharmaceutical company, announced the pricing of a public offering of its common stock and warrants, expected to raise approximately $20 million.GlobeNewswire Inc. · Apr 15, 2025

to start trading

CU

CUECue Biopharma, Inc.

CUE

Pay with—

Available Balance0.00

Your PositionYou don't own any CUE yet.

Related Tickers

Earnings